{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:13:46Z","timestamp":1778753626767,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200176"],"award-info":[{"award-number":["82200176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Shanghai","award":["22ZR1411400"],"award-info":[{"award-number":["22ZR1411400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07024-x","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:24:24Z","timestamp":1776813864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial"],"prefix":"10.1007","volume":"105","author":[{"given":"Xue","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luya","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"7024_CR1","doi-asserted-by":"publisher","first-page":"102898","DOI":"10.1016\/j.ctrv.2025.102898","volume":"134","author":"L Donzelli","year":"2025","unstructured":"Donzelli L, Rocco AD, Petrucci L, Martelli M (2025) Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies. Cancer Treat Rev 134:102898. https:\/\/doi.org\/10.1016\/j.ctrv.2025.102898","journal-title":"Cancer Treat Rev"},{"key":"7024_CR2","doi-asserted-by":"publisher","first-page":"204062072110489","DOI":"10.1177\/20406207211048959","volume":"12","author":"B Fakhri","year":"2021","unstructured":"Fakhri B, Ai W (2021) Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol 12:20406207211048959. https:\/\/doi.org\/10.1177\/20406207211048959","journal-title":"Ther Adv Hematol"},{"key":"7024_CR3","doi-asserted-by":"publisher","first-page":"115369","DOI":"10.1016\/j.ejca.2025.115369","volume":"220","author":"L Renaud","year":"2025","unstructured":"Renaud L, Donzel M, Decroocq J, Decazes P, Galtier J, Burroni B, Veresezan EL, Sesboue C, Dartigues P, Chassagne-Clement C, Martin L, Mauduit C, Kaltenbach S, Penther D, Etancelin P, Sibon D, Bailly S, Martin V, Durot E, Kirova Y, Grenier A, Maerevoet M, Bernard W, Naveau L, Cabannes-Hamy A, Cottereau AS, Jacquet-Francillon N, Noel R, Reichert T, Sarkozy C, Bussot L, Bailly S, Amorim S, Krzisch D, Cornillon J, Legendre H, Chevillon F, Cavalieri D, Sesques P, Minard-Colin V, Haioun C, Morschhauser F, Houot R, Jardin F, Tilly H, Traverse-Glehen A, Camus V (2025) Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines. Eur J Cancer 220:115369. https:\/\/doi.org\/10.1016\/j.ejca.2025.115369","journal-title":"Eur J Cancer"},{"issue":"15","key":"7024_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","volume":"368","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408\u20131416. https:\/\/doi.org\/10.1056\/NEJMoa1214561","journal-title":"N Engl J Med"},{"issue":"1","key":"7024_CR5","doi-asserted-by":"publisher","first-page":"2515337","DOI":"10.1080\/16078454.2025.2515337","volume":"30","author":"M Ma\u2019koseh","year":"2025","unstructured":"Ma\u2019koseh M, Yaseen A, Abed NA, Shahin OA, Abufara A, Halahleh K, Al-Rwashdeh M, Rahman ZA, Al-Rabi K, Abdel-Razeq H (2025) Dose-adjusted EPOCH-R is superior to R-CHOP in Frontline treatment of mediastinal large B-cell lymphoma. Hematology 30(1):2515337. https:\/\/doi.org\/10.1080\/16078454.2025.2515337","journal-title":"Hematology"},{"key":"7024_CR6","doi-asserted-by":"publisher","first-page":"e34570094","DOI":"10.1002\/hon.70094_345","volume":"43","author":"A Cabero Mart\u00ednez","year":"2025","unstructured":"Cabero Mart\u00ednez A, Ferrer Lores B, Garc\u00eda Bacelar A, Mendibil Esquisabel B, N\u00fa\u00f1ez C\u00e9spedes J, Jim\u00e9nez Ubieto A, Arnaldos L\u00f3pez \u00c1, Garc\u00eda Villarroel P, Bao P\u00e9rez L, Brillembourg Cubillan H (2025) Primary mediastinal large B-cell lymphoma: A multicentric observational study of Spanish lymphoma group Geltamo. Hematol Oncol 43:e34570094","journal-title":"Hematol Oncol"},{"issue":"3","key":"7024_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3324\/haematol.2023.283446","volume":"109","author":"MR Cook","year":"2023","unstructured":"Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunleavy K (2023) Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: A systematic review and meta-analysis of 4,068 patients. Haematologica 109(3):846","journal-title":"Haematologica"},{"issue":"4","key":"7024_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.15051","volume":"180","author":"NN Shah","year":"2018","unstructured":"Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE (2018) R-CHOP versus dose\u2010adjusted R\u2010EPOCH in frontline management of primary mediastinal B\u2010cell lymphoma: a multi\u2010centre analysis. Br J Haematol 180(4):534\u2013544","journal-title":"Br J Haematol"},{"issue":"1","key":"7024_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ejh.13337","volume":"104","author":"A Malenda","year":"2020","unstructured":"Malenda A, Ko\u0142kowska-Le\u015bniak A, Pu\u0142a B, D\u0142ugosz\u2010Danecka M, Che\u0142stowska M, Ko\u0144ska A, Giza A, Lech\u2010Mara\u0144da E, Jurczak W, Warzocha K (2020) Outcomes of treatment with dose\u2010adjusted EPOCH\u2010R or R\u2010CHOP in primary mediastinal large B\u2010cell lymphoma. Eur J Haematol 104(1):59\u201366","journal-title":"Eur J Haematol"},{"issue":"24","key":"7024_CR10","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.1002\/cam4.4387","volume":"10","author":"Y Morgenstern","year":"2021","unstructured":"Morgenstern Y, Aumann S, Goldschmidt N, Gatt ME, Nachmias B, Horowitz NA (2021) Dose-adjusted EPOCH\u2010R is not superior to sequential R\u2010CHOP\/R\u2010ICE as a frontline treatment for newly diagnosed primary mediastinal B\u2010cell lymphoma: Results of a bi\u2010center retrospective study. Cancer Med 10(24):8866\u20138875","journal-title":"Cancer Med"},{"issue":"3","key":"7024_CR11","doi-asserted-by":"publisher","first-page":"e70060","DOI":"10.1002\/hon.70060","volume":"43","author":"R Noel","year":"2025","unstructured":"Noel R, Oca CMd, Sfumato P, Calleja A, Collignon A, Villetard F, Schiano de Collela JM, Benizri F, Dutari P, Castoldi C (2025) Long-term outcomes and management strategies with DA\u2010R\u2010EPOCH in primary mediastinal B\u2010cell lymphoma: Insights from a single\u2010center experience. Hematol Oncol 43(3):e70060","journal-title":"Hematol Oncol"},{"issue":"7","key":"7024_CR12","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1097\/HS9.0000000000000917","volume":"7","author":"G Held","year":"2023","unstructured":"Held G, Thurner L, Poeschel V, Ott G, Schmidt C, Christofyllakis K, Viardot A, Borchmann P, Engel-Riedel W, Frickhofen N (2023) Radiation and dose\u2010densification of R\u2010CHOP in primary mediastinal B\u2010cell lymphoma: Subgroup analysis of the UNFOLDER trial. Hemasphere 7(7):e917","journal-title":"Hemasphere"},{"issue":"21","key":"7024_CR13","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","volume":"32","author":"CS Moskowitz","year":"2014","unstructured":"Moskowitz CS, Chou JF, Wolden SL, Bernstein JL, Malhotra J, Novetsky Friedman D, Mubdi NZ, Leisenring WM, Stovall M, Hammond S, Smith SA, Henderson TO, Boice JD, Hudson MM, Diller LR, Bhatia S, Kenney LB, Neglia JP, Begg CB, Robison LL, Oeffinger KC (2014) Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol 32(21):2217\u20132223. https:\/\/doi.org\/10.1200\/JCO.2013.54.4601","journal-title":"J Clin Oncol"},{"issue":"4","key":"7024_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"35","key":"7024_CR15","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1200\/JCO-25-00925","volume":"43","author":"F Morschhauser","year":"2025","unstructured":"Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trn\u011bn\u00fd M, Lenz G, Sharman JP, Herbaux C, Burke JM (2025) Five-year outcomes of the POLARIX study comparing Pola-R-CHP and R-CHOP in patients with diffuse large B-cell lymphoma. J Clin Oncol 43(35):3698\u20133705. https:\/\/doi.org\/10.1200\/JCO-25-00925","journal-title":"J Clin Oncol"},{"issue":"16","key":"7024_CR16","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood.2022017734","volume":"141","author":"Y Song","year":"2023","unstructured":"Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K (2023) Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood 141(16):1971\u20131981. https:\/\/doi.org\/10.1182\/blood.2022017734","journal-title":"Blood"},{"key":"7024_CR17","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1182\/blood-2019-128580","volume":"134","author":"AN Audino","year":"2019","unstructured":"Audino AN, Barth MJ, Tiwari A, Edani D, Ayello J, Harrison L, Morris E, Hochberg JC, Goldman S, Klein C (2019) Polatuzumab vedotin, an antibody-drug conjugate targeting CD79b, is a highly active agent against burkitt lymphoma and primary mediastinal B-cell lymphoma. Blood 134:3963","journal-title":"Blood"},{"issue":"19","key":"7024_CR18","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1182\/bloodadvances.2021004778","volume":"5","author":"V Camus","year":"2021","unstructured":"Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau MP, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse-Glehen A, Decazes P, Becker S, Berriolo-Riedinger A, Tilly H (2021) Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv 5(19):3862\u20133872. https:\/\/doi.org\/10.1182\/bloodadvances.2021004778","journal-title":"Blood Adv"},{"issue":"8","key":"7024_CR19","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1007\/s00277-025-06526-4","volume":"104","author":"Y Ren","year":"2025","unstructured":"Ren Y, Cheng L, Zhuang J, Wang Z, Yuan L, Cheng Z, Ke Y, Wang W, Li J, Liu P (2025) Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0\u20131 DLBCL patients. Ann Hematol 104(8):4165\u20134173","journal-title":"Ann Hematol"},{"issue":"11","key":"7024_CR20","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","volume":"7","author":"RC Lynch","year":"2023","unstructured":"Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, Morris K, Lee S, Rasmussen H, Ottemiller S, Shelby M, Keo S, Verni K, Kurtz DM, Alizadeh AA, Chabon JJ, Hogan GJ, Schulz A, Gooley T, Voutsinas JM, Gopal AK (2023) Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv 7(11):2449\u20132458. https:\/\/doi.org\/10.1182\/bloodadvances.2022009145","journal-title":"Blood Adv"},{"issue":"3","key":"7024_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/annonc\/mdq418","volume":"22","author":"M Rieger","year":"2011","unstructured":"Rieger M, \u00d6sterborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M, Ho AJAO (2011) Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera international trial group study. Ann Oncol 22(3):664\u2013670","journal-title":"Ann Oncol"},{"key":"7024_CR22","doi-asserted-by":"crossref","unstructured":"Picardi M, Giordano C, Pugliese N, Mascolo M, Varricchio S, Troncone G, Vigliar E, Bellavicine C, Lamagna M, Lisi D (2024) Liposomal-encapsulated doxorubicin supercharge\u2010containing front\u2010line treatment improves response rates in primary mediastinal large B\u2010cell lymphoma and mediastinal gray zone lymphoma. Hematol Oncol 42 (1)","DOI":"10.1002\/hon.3247"},{"issue":"6","key":"7024_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/myc.12161","volume":"57","author":"A Candoni","year":"2014","unstructured":"Candoni A, Caira M, Cesaro S, Busca A, Giacchino M, Fanci R, Delia M, Nosari A, Bonini A, Cattaneo C (2014) Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study. Mycoses 57(6):342\u2013350","journal-title":"Mycoses"},{"issue":"3","key":"7024_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1600-0609.2008.01096.x","volume":"81","author":"M Caira","year":"2008","unstructured":"Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT, Nosari A, Candoni A, Bonini A, Mattei D (2008) Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol 81(3):242\u2013243","journal-title":"Eur J Haematol"},{"issue":"5","key":"7024_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F, Rascato MG, Della Pepa R, D\u2019Ambrosio A, Vigliar E (2022) Liposomal doxorubicin supercharge-containing front\u2010line treatment in patients with advanced\u2010stage diffuse large B\u2010cell lymphoma or classical Hodgkin lymphoma: preliminary results of a single\u2010centre phase II study. Br J Haematol 198(5):847\u2013860","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"7024_CR26","doi-asserted-by":"publisher","first-page":"9551","DOI":"10.1182\/blood-2022-166181","volume":"140","author":"A Santarsieri","year":"2022","unstructured":"Santarsieri A, Bennett R, Hopkins D, Lewis KL, Gyansah CN, Cooke L, Nagumantry SK, Shah NK, Cheah CY, McKay P (2022) R-DA-EPOCH treatment is highly effective therapy for primary mediastinal large B-cell lymphoma: a real-world multi-centre retrospective evaluation. Blood 140(Supplement 1):9551\u20139553","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07024-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:57Z","timestamp":1778750577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07024-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7024"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07024-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University in accordance with Declaration of Helsinki (Approval No. B2023-184). All patients signed informed consents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study obtained written informed consent from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}